Liquidia's Yutrepia Generates $130 Million in First-Quarter 2026 Sales

Earnings
โดย Zacks Investment Research·Read original
Summary · why it matters

Liquidia Corporation's Yutrepia generated approximately $130 million in first-quarter 2026 sales following its June 2025 launch. The inhaled dry-powder treprostinil therapy for pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease has seen robust adoption, with more than 4,500 unique prescriptions, around 3,750 patients initiating treatment, and nearly 1,000 physicians prescribing the drug. Liquidia is also advancing L606, an investigational liposomal treprostinil formulation, in clinical trials and plans to expand Yutrepia into additional indications including PH-COPD, IPF, PPF, and Raynaud's phenomenon. The company faces competition from United Therapeutics' Tyvaso franchise and Johnson & Johnson's PAH portfolio, while generic Tyvaso entered the U.S. market in 2026. Liquidia shares have surged 134.6% year to date and currently carry a Zacks Rank of 1, or Strong Buy.

Impact on stocks 3

Biotech & Genomic Medicine± Mixed · 3 stocks
Liquidia Technologies Inc
LQDA
▲ PositiveDemandrelevance

Yutrepia generated $130M in Q1 2026 sales with strong adoption (4,500+ scripts, 3,750 patients, 1,000 prescribers).

United Therapeutics Corporation
UTHR
▼ NegativeCompetitionrelevance

Liquidia's Yutrepia competes with United Therapeutics' Tyvaso franchise, and generic Tyvaso entered the market in 2026, pressuring UT's position.

Johnson & Johnson
JNJ
± MixedCompetitionrelevance

Johnson & Johnson's PAH portfolio is mentioned as a competitor, but no specific impact on J&J is detailed.

© 2026 MarketDXNews